IVF age limit should be raised

NHS IVF clinical trials

Houston Fertility Institute (HFI) is proud to announce its participation in a clinical trial for a new investigational in vitro fertilization (IVF) treatment. This trial, the Thrive-IVF Research Study, is for patients who have previously not been successful with IVF. HFI is one of 20 participating sites chosen from around the country.

What is IVF?

In vitro fertilization is a procedure in which oocytes (eggs) are retrieved from the ovaries and then fertilized by sperm in the laboratory. In nearly all cases, women receive medications to allow the ovaries to produce multiple eggs. After fertilization, the resulting embryos are grown in culture for three to five days, and then embryo(s) are transferred into the uterus. Extra embryos are frozen (cryopreserved) for later use. The process of transferring cryopreserved embryo is referred to as an “FET”.

Who is eligible to participate in this study?

The majority of women undergoing IVF between the ages of 21 and 38 years will to achieve a pregnancy and deliver a healthy baby. Unfortunately, some women will not have a successful pregnancy despite several attempts with IVF and FET.

This study is evaluating patients between 21 and 38 years of age who have not had a successful pregnancy with IVF and FET. Women who have had good quality embryos transferred in three cycles and have not had a successful pregnancy are being recruited to participate. Two of the cycles must be in a “fresh” IVF cycle. Patients who have had negative pregnancy tests or early pregnancy losses in these cycles are eligible.

What is the study examining?

This study is examining the ability of a chemical called granulocyte colony stimulating factor (G-CSF) to increase ongoing pregnancy rates in patients who have not been successful in previous IVF cycles. This chemical is normally produced by white blood cells (also called leukocytes) in the body. The G-CSF used in this study is produced in the laboratory and is called “NT100”. NT100 is an investigational drug.

Preliminary studies have shown that G-CSF, when added to culture medium, may improve embryo quality. In addition, initial studies (in other similar G-CSF products) have suggested that administration of G-CSF may improve pregnancy rates in patients who have failed to have embryo implantation and may also improve ongoing pregnancy rates in patients who have had early pregnancy losses.

LAP LAMBERT Academic Publishing The Patients Voice in HIV/AIDS Clinical Trial Participation: What motivates the willingness of HIV infected people to take part in HIV/AIDS clinical trials?
Book (LAP LAMBERT Academic Publishing)
  • Used Book in Good Condition

Call to step up the pace of TB-HIV collaborative activities  — Weekly Blitz
Discovery by biomedical research of new and improved interventions can get into the bucket of implementation.

Related Posts